{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:04:53Z","timestamp":1781305493564,"version":"3.54.1"},"reference-count":73,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Management of invasive fungal infections is challenging with growing antifungal resistance. Broad antifungal use has resulted in greater intrinsic and acquired resistance among <jats:italic>Candida<\/jats:italic> spp. It is important for clinicians to recognize the relationship between host susceptibility, site of infection, <jats:italic>Candida<\/jats:italic> resistance profiles, specific drug pharmacokinetics and pharmacodynamics, and the role of novel antifungal agents. This narrative review covers the role of rezafungin, ibrexafungerp, and fosmanogepix in the management of invasive candidiasis (IC). The PubMed Database, Embase, and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> were searched between January 2006 and January 2024 using the following terms: rezafungin, CD101, ibrexafungerp, SCY\u2010078, fosmanogepix, APX001, candidemia, and invasive candidiasis. Review articles, prospective clinical trials, and observational studies published in the English language were reviewed. Studies evaluating pharmacology, pharmacokinetics, efficacy, and safety in animals and humans were also reviewed. Promising data continues to emerge in support of novel drug therapies for IC and candidemia. Rezafungin possesses a unique pharmacodynamic profile that might be advantageous compared to other echinocandins, with a practical, once\u2010weekly dosing interval. Ibrexafungerp, currently approved for vulvovaginal candidiasis, has been studied off\u2010label for use in IC and candidemia, and initial data is encouraging. Lastly, fosmanogepix, a mechanistically novel, investigational antifungal agent, may be a potential future option in the management of IC and candidemia. Future research is needed to evaluate the potential use of these agents among diverse patient populations.<\/jats:p>","DOI":"10.1002\/phar.2926","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T06:24:42Z","timestamp":1715235882000},"page":"467-479","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7710-7824","authenticated-orcid":false,"given":"Benjamin A.","family":"August","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services Henry Ford Hospital  Detroit Michigan USA"},{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science Wayne State University  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-7710","authenticated-orcid":false,"given":"Pramodini B.","family":"Kale\u2010Pradhan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science Wayne State University  Detroit Michigan USA"},{"name":"Department of Pharmacy Services, Ascension St. John Hospital  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Invasive Candidiasis","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad139"},{"key":"e_1_2_10_4_1","unstructured":"Rezzayo (rezafungin) [package insert]. Melinta Therapeutics LLC. Lincolnshire IL.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217417s000lbl.pdf. [Accessed June 28 2023]"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1380"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof7030163"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S375625"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9090539"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040262"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02603-17"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00701-16"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq081"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01750-17"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myv108"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix131"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2086120"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00027-12"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03255-14"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.02.013"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw214"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02438-19"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02614-17"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01572-18"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-16"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02324-8"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.546"},{"key":"e_1_2_10_28_1","volume-title":"Statistics","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-023-00759-5"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01611-0"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1890026"},{"key":"e_1_2_10_32_1","unstructured":"Ibrexafungerp (Brexafemme) [package insert]. Scynexis Inc. Jersey City NJ.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214900s002lbl.pdf. [Accessed January 29 2024]"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00833-17"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00161-17"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01692-19"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.906563"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02694-20"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.925"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105922"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02136-19"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz277"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.064"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2021.03.005"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.524"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myac072.P056"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myac072.P057"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.123"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1432"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof8050440"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000111"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004668"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-13"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040239"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.29200\/acsmedchemrev-v54.ch10"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01623-22"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad269"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02542-17"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky302"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01124-20"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad256"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01419-22"},{"key":"e_1_2_10_62_1","volume-title":"REDBOOK [Database on the Internet]","author":"IBM","year":"2024"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01028-22"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.04.012"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.09.030"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00099-20"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz390"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.021"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01510-19"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.642358"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00429-20"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01005-15"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01717-21"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9040863"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2926","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:09:47Z","timestamp":1761059387000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/phar.2926"],"URL":"https:\/\/doi.org\/10.1002\/phar.2926","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"2024-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}